Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes
Tóm tắt
Sodium glucose co-transporter 2 (SGLT2) inhibitors lower glycaemia by inducing glycosuria, but raise endogenous glucose production (EGP). Metformin lowers glycaemia mainly by suppressing EGP. We compared the effects of the SGLT2 inhibitor empagliflozin in treatment-naive (TN) and metformin pretreated (Met) patients with type 2 diabetes. A total of 32 TN and 34 patients on a stable dose of metformin, two subgroups of a study that we previously reported, received a mixed meal with double-tracer glucose administration and indirect calorimetry at baseline, after a single 25 mg dose of empagliflozin, and after 4 weeks of treatment with empagliflozin 25 mg/day. At baseline, compared with the TN group, the Met group had higher fasting glycaemia (9.1 ± 1.7 vs 8.2 ± 1.3 mmol/l), lower fasting and postmeal insulin secretion, lower beta cell glucose sensitivity (37 [18] vs 58 [43] pmol min−1 m−2 [mmol/l]−1, median [interquartile range]) and insulin:glucagon ratio, and higher fasting EGP (15.9 [4.3] vs 12.1 [2.7] μmol kgFFM −1 min−1). Change from baseline in fasting EGP after single dose and 4 weeks of treatment with empagliflozin was similar in the Met and TN groups (19.6 [4.2] and 19.0 [2.3] in Met vs 16.2 [3.6] and 15.5 [3.2] μmol kgFFM −1 min−1 in TN for acute and chronic dosing, respectively). Beta cell glucose sensitivity increased less in Met than TN patients, whereas substrate utilisation shifted from carbohydrate to fat more in Met than TN patients. At baseline, Met patients with type 2 diabetes had more advanced disease than TN patients, featuring worse beta cell function and higher EGP. Empagliflozin induced similar glycosuria and metabolic and hormonal responses in Met and TN patients. ClinicalTrials.gov NCT01248364; European Union Clinical Trials Register 2010-018708-99
Tài liệu tham khảo
citation_journal_title=Physiol Rev; citation_title=Biology of human sodium glucose transporters; citation_author=EM Wright, DD Loo, BA Hirayama; citation_volume=91; citation_publication_date=2011; citation_pages=733-794; citation_doi=10.1152/physrev.00055.2009; citation_id=CR1
citation_journal_title=Am J Physiol Cell Physiol; citation_title=Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2; citation_author=CS Hummel, C Lu, DD Loo, BA Hirayama, AA Voss, EM Wright; citation_volume=300; citation_publication_date=2011; citation_pages=C14-C21; citation_doi=10.1152/ajpcell.00388.2010; citation_id=CR2
citation_journal_title=J Am Soc Nephrol; citation_title=SGLT2 mediates glucose reabsorption in the early proximal tubule; citation_author=V Vallon, KA Platt, R Cunard; citation_volume=22; citation_publication_date=2011; citation_pages=104-112; citation_doi=10.1681/ASN.2010030246; citation_id=CR3
Boehringer Ingelheim International GmbH (2015). Jardiance (empagliflozin). Summary of product characteristics. Available from
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002677/WC500168592.pdf
. Accessed 27 Apr 2015
AstraZeneca AB (2015). Forxiga (dapagliflozin). Summary of product characteristics. Available from
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002322/WC500136026.pdf
. Accessed 27 Apr 2015
Janssen-Cilag International NV (2015). Invokana (canagliflozin). Summary of product characteristics. Available from
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002649/WC500156456.pdf
. Accessed 27 Apr 2015
citation_journal_title=Drugs; citation_title=Ipragliflozin: first global approval; citation_author=RM Poole, RT Dungo; citation_volume=74; citation_publication_date=2014; citation_pages=611-617; citation_doi=10.1007/s40265-014-0204-x; citation_id=CR7
citation_journal_title=Drugs; citation_title=Tofogliflozin: first global approval; citation_author=RM Poole, JE Prossler; citation_volume=74; citation_publication_date=2014; citation_pages=939-944; citation_doi=10.1007/s40265-014-0229-1; citation_id=CR8
citation_journal_title=Drugs; citation_title=Luseogliflozin: first global approval; citation_author=A Markham, S Elkinson; citation_volume=74; citation_publication_date=2014; citation_pages=945-950; citation_doi=10.1007/s40265-014-0230-8; citation_id=CR9
citation_journal_title=Clin Pharmacol Ther; citation_title=LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial; citation_author=B Zambrowicz, J Freiman, PM Brown; citation_volume=92; citation_publication_date=2012; citation_pages=158-169; citation_doi=10.1038/clpt.2012.58; citation_id=CR10
citation_journal_title=Diabetes Obes Metab; citation_title=Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin; citation_author=NB Amin, X Wang, SM Jain, DS Lee, G Nucci, JM Rusnak; citation_volume=17; citation_publication_date=2015; citation_pages=591-598; citation_doi=10.1111/dom.12460; citation_id=CR11
citation_journal_title=Diabetes Obes Metab; citation_title=Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes; citation_author=AP Sykes, GL Kemp, R Dobbins; citation_volume=17; citation_publication_date=2015; citation_pages=98-101; citation_doi=10.1111/dom.12393; citation_id=CR12
citation_journal_title=Nat Rev Endocrinol; citation_title=SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects; citation_author=E Ferrannini, A Solini; citation_volume=8; citation_publication_date=2012; citation_pages=495-502; citation_doi=10.1038/nrendo.2011.243; citation_id=CR13
citation_journal_title=Diabetes Obes Metab; citation_title=Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis; citation_author=A Liakos, T Karagiannis, E Athanasiadou; citation_volume=16; citation_publication_date=2014; citation_pages=984-993; citation_doi=10.1111/dom.12307; citation_id=CR14
citation_journal_title=Ther Adv Endocrinol Metab; citation_title=Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus; citation_author=A Liakos, T Karagiannis, E Bekiari, P Boura, A Tsapas; citation_volume=6; citation_publication_date=2015; citation_pages=61-67; citation_doi=10.1177/2042018814560735; citation_id=CR15
citation_journal_title=Drugs; citation_title=Canagliflozin: a review of its use in patients with type 2 diabetes mellitus; citation_author=G Plosker; citation_volume=74; citation_publication_date=2014; citation_pages=807-824; citation_doi=10.1007/s40265-014-0225-5; citation_id=CR16
citation_journal_title=Diabetes Obes Metab; citation_title=Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia; citation_author=J Rosenstock, LJ Seman, A Jelaska; citation_volume=15; citation_publication_date=2013; citation_pages=1154-1160; citation_doi=10.1111/dom.12185; citation_id=CR17
citation_journal_title=Diabetes Care; citation_title=Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes; citation_author=E Ferrannini, A Berk, S Hantel; citation_volume=36; citation_publication_date=2013; citation_pages=4015-4021; citation_doi=10.2337/dc13-0663; citation_id=CR18
citation_journal_title=Diabetes Care; citation_title=Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial; citation_author=HU Häring, L Merker, E Seewaldt-Becker; citation_volume=37; citation_publication_date=2014; citation_pages=1650-1659; citation_doi=10.2337/dc13-2105; citation_id=CR19
citation_journal_title=J Clin Invest; citation_title=Metabolic response to sodium-glucose co-transporter-2 inhibition in type 2 diabetic patients; citation_author=E Ferrannini, E Muscelli, S Frascerra; citation_volume=124; citation_publication_date=2014; citation_pages=499-508; citation_doi=10.1172/JCI72227; citation_id=CR20
citation_journal_title=J Clin Invest; citation_title=Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production; citation_author=A Merovci, C Solis-Herrera, G Daniele; citation_volume=124; citation_publication_date=2014; citation_pages=509-514; citation_doi=10.1172/JCI70704; citation_id=CR21
citation_journal_title=Diabetes; citation_title=Control of blood glucose in the absence of hepatic glucose production during prolonged fasting in mice: induction of renal and intestinal gluconeogenesis by glucagon; citation_author=E Mutel, A Gautier-Stein, A Abdul-Wahed; citation_volume=60; citation_publication_date=2011; citation_pages=3121-3131; citation_doi=10.2337/db11-0571; citation_id=CR22
citation_journal_title=Diabetologia; citation_title=Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes; citation_author=SE Inzucchi, RM Bergenstal, JB Buse; citation_volume=58; citation_publication_date=2015; citation_pages=429-442; citation_doi=10.1007/s00125-014-3460-0; citation_id=CR23
citation_journal_title=N Engl J Med; citation_title=The target of metformin in type 2 diabetes; citation_author=E Ferrannini; citation_volume=371; citation_publication_date=2014; citation_pages=1547-1548; citation_doi=10.1056/NEJMcibr1409796; citation_id=CR24
citation_journal_title=Clin Pharmacol Ther; citation_title=Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes; citation_author=A Gastaldelli, A Casolaro, M Pettiti; citation_volume=81; citation_publication_date=2007; citation_pages=205-212; citation_doi=10.1038/sj.clpt.6100034; citation_id=CR25
citation_journal_title=Am J Clin Nutr; citation_title=Total body water volumes for adult males and females estimated from simple anthropometric measurements; citation_author=PE Watson, ID Watson, RD Batt; citation_volume=33; citation_publication_date=1980; citation_pages=27-39; citation_id=CR26
citation_journal_title=Comput Methods Prog Biomed; citation_title=A circulatory model for calculating non-steady-state glucose fluxes. Validation and comparison with compartmental models; citation_author=A Mari, L Stojanovska, J Proietto, AW Thorburn; citation_volume=71; citation_publication_date=2003; citation_pages=269-281; citation_doi=10.1016/S0169-2607(02)00097-4; citation_id=CR27
citation_journal_title=Metabolism; citation_title=The theoretical bases of indirect calorimetry: a review; citation_author=E Ferrannini; citation_volume=37; citation_publication_date=1988; citation_pages=287-301; citation_doi=10.1016/0026-0495(88)90110-2; citation_id=CR28
citation_journal_title=Am J Physiol Endocrinol Metab; citation_title=Meal and oral glucose tests for assessment of β-cell action: modelling analysis in normal subjects; citation_author=A Mari, O Schmitz, A Gastaldelli, T Oestergaard, B Nyholm, E Ferrannini; citation_volume=283; citation_publication_date=2002; citation_pages=E1159-E1166; citation_doi=10.1152/ajpendo.00093.2002; citation_id=CR29
citation_journal_title=Diabetes; citation_title=Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance; citation_author=E Cauter, F Mestrez, J Sturis, KS Polonsky; citation_volume=41; citation_publication_date=1992; citation_pages=368-377; citation_doi=10.2337/diab.41.3.368; citation_id=CR30
citation_journal_title=Diabetes Res Clin Pract; citation_title=Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?; citation_author=T Wu, SS Thazhath, MJ Bound, KL Jones, M Horowitz, CK Rayner; citation_volume=106; citation_publication_date=2014; citation_pages=e3-e6; citation_doi=10.1016/j.diabres.2014.08.004; citation_id=CR31
citation_journal_title=Metabolism; citation_title=Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus; citation_author=J Cuthbertson, S Patterson, FP O’Harte, PM Bell; citation_volume=60; citation_publication_date=2011; citation_pages=52-56; citation_doi=10.1016/j.metabol.2010.01.001; citation_id=CR32
citation_journal_title=Diabetes Care; citation_title=Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition; citation_author=G Ferrannini, T Hach, S Crowe, A Sanghvi, KD Hall, E Ferrannini; citation_volume=38; citation_publication_date=2015; citation_pages=1730-1735; citation_doi=10.2337/dc15-0355; citation_id=CR33
citation_journal_title=Diabetes Care; citation_title=Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition; citation_author=AL Peters, EO Buschur, JB Buse; citation_volume=38; citation_publication_date=2015; citation_pages=1687-1693; citation_doi=10.2337/dc15-0843; citation_id=CR34